

PBMC
CD56+
CD3-/CD56+
Expansion Fold
Fold Increase
3000
2500
2000
1500
1000
500
0
DAY 0
DAY 6
DAY 10
DAY 14
DAY 17

FIG. 1A



Fold increase
24000
16000
8000
0
PBMC
CD56
PBMC
CD56
W/O IL-21
W/ IL-21
Total PDL
15
10
5
0
PBMC
CD56
PBMC
CD56
W/O IL-21
W/ IL-21

FIG. 1B




FIG. 2



1
2
3
4
5
6
7
8
9
10
11
12
A
B
C
D
E
F
G
H
E:T = 10:1
E:T = 3:1
E:T = 1:1
E:T = 0.5:1
Spontaneous
Maximum release

FIG. 3



W/O IL-21
W/ IL-21
110
55
0
% of lysis
PBMC
CD56+
10:1
3:1
1:1
0.5:1
E:T ratio

FIG. 4A



AGS
A549
MDA-MB-231
% of lysis
80
70
40
35
0
PBCM
CD56
W/O IL-21
W/ IL-21

FIG. 4B



Donor 1
Fold increase
24,000
16,000
8,000
0
D0
D6
D10
D14
D17
No treat
D0-6
D6-10
D10-14
D14-17
Total PDL
14
7
0
D0
D6
D10
D14
D17
No treat
D0-6
D6-10
D10-14
D14-17

FIG. 5A



Fold increase
24,000
16,000
8,000
0
D0
D6
D10
D14
D17
No treat
D0-3
D3-6
D0-6
Total PDL
14
7
7
7
0
D0
D6
D10
D14
D17
No treat
D0-3
D3-6
D0-6

FIG. 5B



Donor 1
Fold increase
16,000
8,000
0
0 ng/ml
10 ng/ml
30 ng/ml
50 ng/ml
D0
D6
D10
D14
D17
Total PDL
14
7
0
Donor 2
3,000
1,500
12
6
Donor 3
6,000
3,000
100 ng/ml

FIG. 6



120
60
0
% of lysis
No treat
D0-6
D6-10
D10-14
D14-17
10:1
3:1
1:1
0.5:1
E:T ratio

FIG. 7A



A
AGS
B
A549
C
MDA-MB-231
% of lysis
80
40
0
70
35
60
30
No treat
D0-6
D6-10
D10-14
D14-17

FIG. 7B



AGS
A549
MDA-MB-231
% of lysis
80
40
0
60
30
No treat
D0-3
D3-6
D0-6

FIG. 7C



120
60
0
% of lysis
0 ng/ml
10 ng/ml
30 ng/ml
50 ng/ml
10:1
3:1
1:1
0.5:1
E:T ratio
120
60
0
% of lysis
0 ng/ml
50 ng/ml
100 ng/ml
10:1
3:1
1:1
0.5:1
E:T ratio

FIG. 8A



AGS
80
40
20
0
% of lysis
0 ng/ml
10 ng/ml
30 ng/ml
50 ng/ml
A549
70
35
0
% of lysis
0 ng/ml
10 ng/ml
30 ng/ml
50 ng/ml
MDA-MB-231
70
35
0
% of lysis
0 ng/ml
10 ng/ml
30 ng/ml
50 ng/ml

FIG. 8B



4.5E+10
3.5E+10
2.5E+10
1.5E+10
5E+09
2E+09
1E+09
0
Fold increase
W/O IL-21
W/ IL-21
Feeder cell Stimulation
Feeder cell Stimulation
D0
D6
D10
D14
D20
D24
D28
D34
D38
D42
40
20
0
Total PDL
W/O IL-21
W/ IL-21
Feeder cell Stimulation
Feeder cell Stimulation
D0
D6
D10
D14
D20
D24
D28
D34
D38
D42

FIG. 9




FIG. 10A




FIG. 10B




FIG. 10C




FIG. 10D



W/O IL2
W/ IL2
UL
0.08
UR
18.39
LL
56.12
LR
25.42
UL
0.87
UR
18.38
LL
80.89
LR
6.87
7-AAD
Annexin V-FITC
% of dead cells
% of live cells
W/O IL-2
W/ IL-2

FIG. 11



Blood Cancer
CCRF-SB
Stomach Cancer
AGS
Pancreatic Cancer
MIA-PACA2
Cholangiocarcinoma
SNU245
Colon Cancer
HCT15
Breast Cancer
MDA-MB-231
100
80
60
40
20
0
1:1 1:10 1:20 1:1 1:10 1:20
W/O IL2 W/ IL2
W/O L2 W/ IL2

FIG. 12



NIH:OVCAR-3 (Ovary/adenocarcinoma)
-IL2 (24hr)
+IL2 (24hr)
None
(E:T) 1:1
0.1:1
0.05:1

FIG. 13



AGS (Stomach/adenocarcinoma)
-IL2 (24hr)
+IL2 (24hr)
None
(E:T) 1:1
0.1:1
0.05:1

FIG. 14